Therapeutic Expertise

Rare & Orphan Diseases

We design and run trials in rare and orphan indications where patient numbers are small and every participant counts. Our approach blends creative small-population design with deep regulatory and recruitment expertise.

Small populationsNatural historyOrphan drug designationGenetic disorders

Rare disease programmes cannot rely on large samples, so design and endpoint choice matter enormously. We use natural-history data, novel and adaptive designs, and partnerships with patient-advocacy groups to recruit efficiently and generate regulatory-grade evidence, while supporting orphan drug and rare paediatric disease designation strategy.

Addressing common pain points in rare & orphan diseases clinical trials

Very small, dispersed patient populations

Recruiting enough patients for a rare indication is the single biggest challenge in orphan research.

Rare & Orphan Diseases solution — Advocacy-led recruitment

We partner with patient registries and advocacy groups and use decentralised models to reach geographically dispersed patients.

Limited precedent for endpoints

Rare diseases often lack validated, regulator-accepted endpoints.

Rare & Orphan Diseases solution — Natural-history and novel endpoints

We leverage natural-history data and develop fit-for-purpose endpoints agreed with regulators early.

Complex regulatory and incentive landscape

Orphan designation, rare paediatric disease vouchers and accelerated pathways add strategic complexity.

Rare & Orphan Diseases solution — Integrated designation strategy

Our regulatory team builds the designation and incentive strategy (ODD, PRV, Fast Track) alongside the clinical plan.

Resources

Rare & Orphan Diseases clinical trial resources

Transforming Rett Syndrome Research

Advancing clinical trials in a rare neurodevelopmental disorder.

Advancing Phelan-McDermid Syndrome Research

Trial design considerations in an ultra-rare genetic disease.

Evidence & insights

Rare & Orphan Diseases white papers

Open-access reports from our physicians and data science teams — free, no sign-in.

Generalized Anxiety Disorder - Clinical Endpoints, FDA Approvals, and Trial Enhancements

White paper · PDF ↗

Understanding ADHD Clinical Trials

White paper · PDF ↗

Browse all 54 white papers →

The iNGENū CRO difference

Australian expertise, direct FDA submission

We uniquely combine Australian expertise with direct FDA submission capabilities, offering a streamlined path for sponsors to achieve global approval. Trial data from Australia can be submitted directly to the FDA via our E-Gateway, eliminating the need for third-party intermediaries.

iNGENū takes a highly strategic and disciplined approach to clinical research, ensuring every dollar is directed toward generating meaningful outcomes — eliminating unnecessary costs while maintaining the highest scientific and regulatory standards across the Asia-Pacific region.

“We have been using iNGENū for a Phase 1, first-in-human trial of our investigational drug — medical writing, project management, clinical data management and full end-to-end execution and monitoring. We have been particularly impressed by the out-of-the-box creative solutions to speed up and reduce overheads during this clinical trial.”

Giles MossChief Executive Officer

Ready to discuss your Rare & Orphan Diseases clinical trial?

Talk to our team about how iNGENū CRO can accelerate your research.

Request a proposal